Comparison of Diurnal Intraocular Pressure Control by Latanoprost versus Travoprost
Comparison of Diurnal Intraocular Pressure Control by Latanoprost versus Travoprost
复制标题
拉坦前列素与曲伏前列素控制昼夜眼压的比较
DOI：
--
复制
发表时间：
2006
影响因子：
3.2
通讯作者：
G. Berdeaux
中科院分区：
文献类型：
--
作者：
P. Denis;R. Launois;M. Devaux;G. Berdeaux
摘要背景与目的：眼压（IOP）每天都有波动，其发生是青光眼发展的危险因素。通过药物控制白天眼压是一个重要的治疗靶点。我们开始比较曲伏前列素和拉坦前列素的IOP控制，考虑到最后一次滴注的时间和IOP测量的时间。
AbstractBackground and objective: Intraocular pressure (IOP) is known to be subject to daily fluctuations, the occurrence of which is a risk factor for progression of glaucoma. Control of IOP during the day by drugs is an important therapeutic target. We set out to compare the IOP control of travoprost and latanoprost taking into account the time since last instillation and the time of IOP measurement.
Methods: This was a prospective, cross-sectional observational study with some retrospective data collection. Private ophthalmologists were selected to each recruit ten patients with primary open-angle glaucoma and/or ocular hypertension receiving either travoprost or latanoprost as monotherapy. Clinical endpoints included IOP measurements and percentage of patients attaining predefined target IOPs. Six patient subgroups were defined according to: (a) IOP measurement time: before 1200h, 1200h–1600h and after 1600h, and (b) time since last intake (<24 hours, >24 hours). Analyses comprised ϰ 2 and Wilcoxon tests, ANOVA, logistic regressions and adjustment by propensity score.
Results: In total, 2052 patients treated with travoprost (n = 1704) or latanoprost (n = 348) participated in the study. Treatment groups were comparable at baseline, except for a longer treatment duration in latanoprost-treated patients. When the interval between the last treatment instillation and IOP measurement (treatment/ IOP interval) was <24 hours (n = 1241), 82% of travoprost-treated patients attained pre-defined target IOP versus 67% with latanoprost (p < 0.0001). This difference was greatest after 1600h, when the mean IOP was 16.5mm Hg for travoprost-treated patients and 17.7mm Hg for latanoprost-treated patients (p = 0.0025). When the treatment/IOP interval was >24 hours (n = 461), travoprost was superior to latanoprost, i.e. more patients using travoprost attained the predefined target IOP (78.5% vs 68.3%; p = 0.0344), and the mean IOP value was lower in the travoprost group (16.8 vs 17.8mm Hg; p = 0.0016). After adjustments for confounding factors, similar results were obtained.
Conclusions: According to this observational survey, travoprost appears to reduce evening and mean diurnal IOP more effectively than latanoprost. Latanoprost IOP control appears to be more sensitive to time since the last dose.